Zhang et al. also described 11 ALK receptor tyrosine kinase gene (ALK)-positive patients with pathologically confirmed N2 NSCLC who were treated with neoadjuvant crizotinib and suggested that neoadjuvant crizotinib might be feasible and well tolerated in locally advanced diseases for complete resection (21). The gene discussed is ALK; the disease is non-small cell lung carcinoma.